Dr. Tolkachjov is a speaker/investigator for CASTLE Biosciences, Kerecis, Boehringer Ingelheim, Regeneron, and Bioventus/LifeNet. The authors declare no conflicts of interest. The authors have nothing to report.
No takes yet. Share an insight, caveat, or question.
Limmer et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: